Moreover, due to the broad expression of SWI/SNF subunits in cells, adverse side effects such as differentiation syndrome, hyperbilirubinemia, etc., were observed in patients treated with FHD-286 in phase 1 clinical trials (Dinardo et al., 2025). This evidence concerns the gene SMARCA1 and Hyperbilirubinemia.